Design Therapeutics (DSGN) Return on Capital Employed (2021 - 2026)

Design Therapeutics has disclosed Return on Capital Employed across 6 years of filings, most recently posting 36.1% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 36.1%, down 719.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 36.1% (down 719.0% YoY), and the FY2025 annual result was 35.15%, down 1137.0% from the prior year.
• Return on Capital Employed came in at 36.1% for Q1 2026 at Design Therapeutics, up from 38.59% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 11.48% in Q1 2022 to a low of 38.59% in Q4 2025.
• The 5-year median for Return on Capital Employed is 25.6% (2024), against an average of 25.98%.
• Across the five-year window, Return on Capital Employed surged 456 bps in 2024 and slumped 1428 bps in 2025, its largest moves.
• Design Therapeutics' Return on Capital Employed stood at 20.05% in 2022, then plunged by 37 bps to 27.42% in 2023, then advanced by 8 bps to 25.11% in 2024, then tumbled by 54 bps to 38.59% in 2025, then climbed by 6 bps to 36.1% in 2026.
• The last three Return on Capital Employed figures came in at 36.1% (Q1 2026), 38.59% (Q4 2025), and 37.83% (Q3 2025), per Business Quant data.